Treatment exposure
Prior to crossover, the median number of pertuzumab or placebo cycles administered to patients was 22.0 (range 1–4) and 17.0 (range 1–68), over the respective median duration of 66.1 weeks (range 3–225) and 52.3 weeks (range 3–207). The median number of trastuzumab cycles in the pertuzumab and placebo arms was 22.0 (range 1–74) and 17.0 (range 1–74), respectively. Both arms had a similar median number of docetaxel cycles, with 7.0 (range 1–26) in the pertuzumab arm and 6.5 (range 1–22) in the placebo arm. The median dose of each was 900.0 mg and 826.1 mg. Following crossover, the median number of pertuzumab cycles was 6.0 (range 4–8), with a median duration of 18.1 weeks (range 12–24).